anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
FIELD: medicine. SUBSTANCE: method involves concurrently acting upon fibrinolysis, reducing blood platelets aggregation and increasing injured eye tissue antioxidation protection. To do it, autoplasma supernatant is administered in parabulbar and parenteral mode. Supernatant is produced as a result of irreversible blood platelets aggregation with concurrent application of adenosine triphosphate in the amount of 0.3-0.4 mg/ml and thrombin in the amount of 0.1-0.3 ED/ml. EFFECT: enhanced effectiveness of treatment. 4 cl, 3 tbl
Disturbance in the mitochondrial electron transport chain (ETC) is a key factor in the emerging discovery of immune cell activation in inflammatory diseases, yet specific regulation of ETC homeostasis is extremely challenging. In this paper, a mitochondrial complex biomimetic nanozyme (MCBN), which plays the role of an artificial "VI" complex and acts as an electron and free radical conversion factory to regulate ETC homeostasis is creatively developed. MCBN is composed of bovine serum albumin (BSA), polyethylene glycol (PEG), and triphenylphosphine (TPP) hierarchically encapsulating MnO2 polycrystalline particles. It has nanoscale size and biological properties like natural complexes. In vivo and in vitro experiments confirm that MCBN can target the mitochondrial complexes of inflammatory macrophages, absorb excess electrons in ETC, and convert the electrons to decompose H2O2. By reducing the ROS and ATP bursts and converting existing free radicals, inhibiting NLRP3 inflammatory vesicle activation and NF-κB signaling pathway, MCBN effectively suppresses macrophage M1 activation and inflammatory factor secretion. It also demonstrates good inflammation control and significantly alleviates alveolar bone loss in a mouse model of ligation-induced periodontitis. This is the first nanozyme that mimics the mitochondrial complex and regulates ETC, demonstrating the potential application of MCBN in immune diseases.
Understanding the relation between spinopelvic (lumbopelvic) tilt and femoracetabular impingement syndrome (FAIS) is complex, and determining the optimal patient parameters that lead to successful nonoperative management is vital. Physical therapy (PT) focusing on core and posterior chain strengthening is often successful. PT can change the posterior tilt of the pelvis by 5° to 10°, allowing increased range of motion (ROM) and decreased impingement of the hip. However, PT does not change cam anatomy. Thus, PT alone may not sufficiently increase ROM in patients with cam-type impingement and large α angles or limited femoral anteversion. Pelvic compensation may lead to successful nonoperative management of FAIS, but not in all patients. Large-cam, high-flexion athletes with chronic hip pain should try PT. Yet, while some patients with large cam lesions may improve without surgery if femoral version and/or pelvic tilt ROM can be increased, surgery should not be excessively delayed in patients with poor prognostic factors for nonoperative management.
The invention discloses a sweat-suppressing and deodorizing shoe pad and belongs to the technical field of articles for daily use. All used medicines are traditional Chinese medicine powder. The medicines are put in the sandwich layer of the shoe pad. The formula of the used traditional Chinese medicines per ten pairs of shoe pads comprises 5-10g alum, 5-10g of mirabilite, 1-10g of Chinese rhubarb, 2-10g of Ligusticum wallichii, 1-10g of Chinese angelica, 2-10g of rhizoma atractylodis, 1-5g of magnolia flower, 2-10g of Pseudolarix amabilis Rehd, 2-10g of Agastache rugosus, 0.2-0.5g of mint and 2-10g of bamboo charcoal. The medicine powder is prepared by adopting a method which comprises the following steps of: weighing the medicines according to the weight, crushing the medicines, passing through a 400-mesh sieve, evenly mixing, equally dividing the ground traditional Chinese medicine powder into ten parts, evenly spreading the traditional Chinese medicine powder onto the sandwich layers of the shoe pads and finally sewing the shoe pads. The sweat-suppressing and deodorizing shoe pad has the beneficial effects that since all used medicines are pure traditional Chinese medicine preparations, the raw materials are simple and easy to obtain, the cost is low and the shoe pad is easy to popularize; and the shoe pad does not contain hormone and do no harm to human bodies, the deodorizing effect is obvious, the service life is long, the shoe pad is convenient to use and does not hurt the skin and the best use of the shoe pad can be made.
Tumor is a complex and aggressive type of disease that poses significant health challenges. Understanding the cellular mechanisms underlying its progression is crucial for developing effective treatments. In this study, we develop a novel mathematical framework to investigate the role of cellular plasticity and heterogeneity in tumor progression. By leveraging temporal single-cell data, we propose a reaction-convection-diffusion model that effectively captures the spatiotemporal dynamics of tumor cells and macrophages within the tumor microenvironment. Through theoretical analysis, we obtain the estimate of the pulse wave speed and analyze the stability of the homogeneous steady state solutions. Notably, we employe the AddModuleScore function to quantify cellular plasticity. One of the highlights of our approach is the introduction of pulse wave speed as a quantitative measure to precisely gauge the rate of cell phenotype transitions, as well as the novel implementation of the high-plasticity cell state/low-plasticity cell state ratio as an indicator of tumor malignancy. Furthermore, the bifurcation analysis reveals the complex dynamics of tumor cell populations. Our extensive analysis demonstrates that an increased rate of phenotype transition is associated with heightened malignancy, attributable to the tumor's ability to explore a wider phenotypic space. The study also investigates how the proliferation rate and the death rate of tumor cells, phenotypic convection velocity, and the midpoint of the phenotype transition stage affect the speed of tumor cell phenotype transitions and the progression to adenocarcinoma. These insights and quantitative measures can help guide the development of targeted therapeutic strategies to regulate cellular plasticity and control tumor progression effectively.
PURPOSE:To obtain a new compound useful for treating hypertension and ache, specifically inhibiting the actions of angiotensin converting enzymes, enkephalinase and endothelin converting enzyme. CONSTITUTION:A compound shown by formula I (A is single bond or lower alkylene; R1 and R2 are H or aralkyl; Trp is tryptophan residue) such as N-(RS)-[2-(hydroxyaminocarbonyl)-3-methyl-1-oxobutyl]-L-tryptophan. The compound is obtained by amidating a carboxylic acid shown by formula II or a reactive derivative thereof with an amine shown by formula III in a solvent (e.g. pyridine). this compound shows hypotensive action, inhibitory action on bradykinin inactivation, inhibitory action on ANP inactivation and inhibitory action on cerebrovascular contraction and coronary blood vessel contraction. The compound suppresses decomposition of enkephalin and raises opioid activity.
JUVIA zinc containing vaginal gel group. Receive oral fluconazole treatment (150 mg) and after that participants will use a zinc containing- vaginal gel for 12 weeks.
Attention deficit hyperactivity disorder (ADHD) is one of the most common mental disorders among children. Children with ADHD frequently lack organizational, time management, and planning skills. These deficits can cause impaired functioning in multiple settings, including home, school, and peer relationships. Advancements in treatment options for these deficits, however, have been minimal. Previous research has indicated that organizational skills training (OST) is an effective intervention for improving organizational skills in children with ADHD. Its effectiveness relative to other available treatments is unknown. This study will compare the effectiveness of OST with that of contingency management (CM) and a waitlist condition in improving organizational, time management, and planning skills deficits in children with ADHD.

Participants in this study are randomly assigned to OST, CM, or Wait-List (WL). Participants in the OST and CM groups attend 20 1-hour sessions over 10 weeks. OST trains children to use a variety of techniques for improving their organizational skills. Both children and their parents attend every OST session. CM does not involve skills training. Rather, CM trains parents and teachers to identify desired "end" behaviors and to increase the frequency of these behaviors through the use of a structured reward system. Both children and their parents attend every CM session, but the children's participation will be minimal. Participants assigned to the waitlist condition will have the opportunity to receive their choice of either OST or CM once they have completed the study. All participants attend follow-up visits 1 month post-treatment. Participants assigned to OST and CM attend follow-up visits after 1 and 4 months into their next school grade. School performance, feelings about school, ADHD symptoms, organizational skills, family environment, medication or services received, and use of treatment strategies will be assessed at each follow-up visit.
The goal of this research study is to determine whether the use of Eatable Alphabet cards in addition to standard weight management in a primary care setting will increase vegetable consumption. Additional outcomes that will be examined include fruit consumption, child engagement in meal selection and preparation, and clinic follow-up. If the intervention shows a significant effect in the above outcome measures, Eatable Alphabet cards can be implemented as a standard component of obesity management in primary care settings. It is hypothesized that the intervention will increase vegetable consumption, increase child engagement in meal selection and preparation, and increase clinic follow-up.

The study design is randomized control trial, in which the control group includes parent-child dyads receiving care as usual in the weight management program, including nutrition education, and the intervention group includes parent-child dyads receiving care as usual in the weight management program plus Eatable Alphabet cards in addition to typical nutrition education. All study participants will be families receiving care at the POWER Kids Weight Management Program at 410 Lakeville Road, with the child between the ages of 2 and 10 who have overweight or obesity. The primary outcome is parent reported frequency of child vegetable consumption. Secondary outcomes include: parent reported frequency of child fruit consumption, parent reported child engagement in meal selection/preparation, follow-up weight management visit attendance, and child anthropometric outcomes.
Families randomized to this intervention group will receive a self-administered web-based parenting intervention. Parents have access to a weekly 6-modules parenting intervention.
Provided is a novel chymase inhibitor. The chymase inhibitor which comprises a compound represented by general formula (A) as an active ingredient displays selective and excellent inhibition of enzyme activity with respect to human chymase. The compound is preferably one type or more selected from the group consisting of quercitrin, isoquercitrin, hyperoside, kaempferol, and luteolin. A medicine comprising the chymase inhibitor as an active ingredient can suppress production of angiotensin II by suppressing activity of the human chymase, and thus is useful as a drug which is used to prevent and treat various diseases caused by angiotensin II. (In general formula (A), R 1  to R 5  is each independently a hydroxyl group or methoxy group, and X 1  is a hydroxyl group or -OG group. G is a sugar chain.)
PURPOSE:To immobilize an antibody protein retaining high antigen-antibody reaction activity, by bringing the antibody protein into contact with a specific lipid monomolecular film developed on the surface of an aq. phase to form an antibody protein-monomolecular film complex film and then transferring the formed complex film to a solid substrate. CONSTITUTION:A 14-22C long chain fatty acid (e.g., stearic acid) and/or an ester thereof are dissolved in an organic solvent such as chloroform and then developed on the surface of distilled water or an aq. soln. contg. polyvalent metal salt (e.g. barium chloride) and having ordinarily 6.5-7.5pH to form a monomolecular film of the polyvalent metal salt and/or ester of the 14-22C long chain fatty acid. The formed monomolecular film is compressed into a surface pressure of 1-30mN/m. Subsequently, an antibody protein (e.g., immunoglobulin G) is injected into the aq. phase under the monomolecular film and allowed to stand for ordinarily 30min-1hr to form an antibody protein- monomolecular film complex film. The formed complex film is compressed into a surface pressure of 30-50mN/m and then transferred to a hydrophobized solid substrate such as quartz.
Patients in the intervention arm will participate in a supervised in-hospital, exercise training program on a cycle ergometer before and during chemotherapy. At week 5-6 there will be a transition period of in-hospital to home-based exercise training (at this point we will perform the exercises that they will perform at home in the in-hospital environment to ensure that the patient understands the home-based exercise training programme) and then week 7-12 will be home-based exercise training only with telephone support.
The invention concerns fluid pharmaceutical compositions for controlled release of one active substance comprising: a) a therapeutically efficient amount of at least one active substance; b) 3 to 55 wt. % of phospholipid; c) 16 to 72 wt. % of one or several pharmaceutically acceptable solvents; and d) 4 to 52 wt. % of at least one fatty acid. Said composition is characterised in that it has the property of being instantaneously gelled in the presence of an aqueous phase. The invention also concerns methods for preparing said compositions and their use for treating a human being or animal.
OBJECTIVES: I. Compare pathological response, recurrence-free interval, and survival in patients with optimal stage III epithelial ovarian cancer or primary peritoneal carcinoma receiving intravenous (IV) paclitaxel and cisplatin vs IV paclitaxel and intraperitoneal (IP) cisplatin plus IP paclitaxel. II. Compare the toxic effects and complications of these 2 treatment regimens in these patients. III. Determine the frequency and prognostic significance of BRCA1 and BRCA2 mutations in these patients. IV. Determine the effect of non-genetic risk factors on the course of disease in BRCA1- and BRCA2-related ovarian cancer or primary peritoneal carcinoma. V. Compare the quality of life of these patients receiving these treatments.

OUTLINE: This is a randomized study. Patients are stratified according to gross residual disease (present vs absent) and whether second-look surgery will be performed at the end of treatment (yes vs no). Blood is drawn for BRCA mutation analysis and DNA extraction before the start of chemotherapy, but after randomization. Patients are randomized to one of two treatment arms. Patients in arm I receive IV paclitaxel by 24-hour infusion on day 1 followed by IV cisplatin on day 2. Patients in arm II receive IV paclitaxel by 24-hour infusion on day 1 followed by intraperitoneal (IP) cisplatin on day 2, plus IP paclitaxel on day 8. Treatment for both arms repeats every 3 weeks for a total of 6 treatment courses. Following chemotherapy, second look surgery is performed if selected by the patient. Quality-of-life assessments are performed prior to randomization, prior to course 4, 3-6 weeks after the completion of course 6 and prior to second look surgery if selected, 6 months after treatment is completed, and 12 months after treatment is completed. Patients are followed every 3 months for 2 years, then every 6 months thereafter.

PROJECTED ACCRUAL: Approximately 384 patients will be accrued for this study within 16 months.
The utility model discloses a dual-functional domestic lamp, belonging to a medical and health care device for family use and an illuminating device. Among the existing medical and health care devices for family use or the illuminating devices, the species and using effects thereof can not satisfy the daily living and medical care needs of people. The utility model provides a double functional lamp, which can not only illuminate but also treat diseases. The treating lamp head thereof can shoot out the radiator which simulates the spectrum of human body. The holding body of the radiator is provided with various models. So the dual-functional domestic lamp can treat various diseases. According to the different adoptions of the holding bodies and the radiators, the dual-functional domestic lamp has visible therapeutic effects to the three aspects diseases of blood circulation, etc.
AIMS: Adults with intellectual disabilities (ID) are known to have poor oral health and complex dental needs requiring treatment under general anesthesia (GA). This retrospective chart review aimed to provide information on the oral health status and treatment needs of adults with ID in Auckland.
METHODS AND RESULTS: Data on 1075 adult patients with ID seen through the Auckland public dental service during the period June 2016 to April 2020 were drawn from electronic notes. Analyses focused on age group differences and the characteristics associated with the use of GA for dental treatment. More cumulative caries experience, poorer oral hygiene, and more missing teeth were observed among those who were older. About half (50.8%) of the patients used GA for dental treatment. This proportion was higher among those who were younger, less independent, non-verbal, with poorer oral hygiene, or who had active decay.
CONCLUSION: Adults with ID are a heterogeneous population with unmet dental treatment needs. Different age groups require consideration of distinct characteristics for dental care provision. It is important to be for public sector service provision to be developed to consider predictors for GA service use in patients who are younger, less independent, non-verbal, or have active decay.
Two sets of patients were made (10 patients/set) using random-generated numbers created by a computer program (Excel sheet). Conventional complete denture will be fabricated first and patient will wear the denture for 3 months. Then 4 implants will be placed according to all in 4 concept.after 3 months of asseointegration,the first 10 participants will recieve metal framework first. After 3 months, patient satisfaction and oral healthy related quality of lifewill be measured.
Subsequent to a medical examination, a 61-year-old male was referred to our hospital with jaundice. He was diagnosed with intrahepatic cholangiocarcinoma involving the hepatic hilum and was referred to our department to undergo a left trisectionectomy of the liver, extrahepatic bile duct resection, and regional lymphadenectomy. He was discharged on postoperative day 39 without liver failure. Two months postoperatively, positron-emission tomography/computed tomography(PET/ CT)indicated recurrences in the bone, and paraaortic lymph node. Gemcitabine and cisplatin combination first-line therapy was administered. Disease progression occurred after 4 courses of therapy. Gene panel testing was performed and the patient was switched to pembrolizumab owing to high microsatellite instability. After 2 courses of pembrolizumab, notable shrinkage of the paraaortic lymph node recurrence was confirmed on computed tomography as well as a partial response. PET-CT revealed disappearance of abnormal accumulation in all lesions at 20 months postoperatively. This has been sustained for 24 months following surgery without remarkable immune-related side-effects.
A vitamin-oil concentrate is homogenised in an aqueous solution of lactose and gum arabic or gum ghatti and the homogenised mixture is spray dried to give a powdery free flowing product. The vitamins which may be used are vitamins A, D2, D3, E, K and provitamin A. Preferably the concentrate is stabilised before homogenising by addition of antioxidants and chelating agents such as butylated hydroxy toluene, butylated hydroxy anisole, propyl gallate, norhydroguaiaretic acid, citric acid and ethylene diamine tetra-acetic acid.  The ratio of gum arabic or gum ghatti to lactose may lie within the range 1 : 2 to 9 : 1, and the total solids concentration in the aqueous solution between 10 and 40%.  A small proportion of an anticaking agent such as calcined calcium silicate, calcium stearate, or magnesium stearate may be added to the powdery dry homogenised mixture to improve its free-flowing properties.ALSO:A vitamin-oil concentrate is homogenised in an aqueous solution of lactose and gum arabic or gum ghatti and the homogenised mixture is spray dried to give a powdery free-flowing product. The vitamins which may be used are vitamins A, D2, D3, E, K and provitamin A. Preferably the concentrate is stabilised before homogenising by addition of antioxidants and chelating agents such as butylated hydroxy toluene, butylated hydroxy anisole, propyl gallate, norhydroguaiaretic acid, citric acid and ethylene diamine tetra-acetic acid.  The ratio of gum arabic or gum ghatti to lactose may lie within the range of 1:2 to 9:1, and the total solids concentration in the aqueous solution between 10 and 40%.  A small proportion of an anti-caking agent such as calcined calcium silicate, calcium stearate or magnesium stearate may be added to the powdery dry homogenised mixture to improve its free-flowing properties.
PROBLEM TO BE SOLVED: To provide a novel circadian rhythm improvement agent.SOLUTION: The technical characteristics of the present invention to solve the aforementioned problem are as follows. 1. A circadian rhythm improving agent containing passion flower extract (excluding those containing harmine). 2. The circadian rhythm improving agent described in 1. characterized by having an effect of adjusting the amplitude and/or the periodic length of the expressed rhythm of a clock gene. 3. The circadian rhythm improving agent described in 2. characterized in that the clock gene is the Per2 gene and/or the Cry2 gene. 4. The circadian rhythm improving agent described in any one of 1. to 3. characterized in that the passion flower extract comprises at least one selected from isovitexin, isoschaftoside, homoorientin, schaftoside, isovitexin-2"-O-glucoside and derivatives thereof.SELECTED DRAWING: None
Muscle atrophy resulting from peripheral nerve injury (PNI) poses a threat to a patient's mobility and sensitivity. However, an effective method to inhibit muscle atrophy following PNI remains elusive. Drawing inspiration from the sea cucumber, we have integrated microneedles (MNs) and microchannel technology into nerve guidance conduits (NGCs) to develop bionic microneedle NGCs (MNGCs) that emulate the structure and piezoelectric function of sea cucumbers. Morphologically, MNGCs feature an outer surface with outward-pointing needle tips capable of applying electrical stimulation to denervated muscles. Simultaneously, the interior contains microchannels designed to guide the migration of Schwann cells (SCs). Physiologically, the incorporation of conductive reduced graphene oxide and piezoelectric zinc oxide nanoparticles into the polycaprolactone scaffold enhances conductivity and piezoelectric properties, facilitating SCs' migration, myelin regeneration, axon growth, and the restoration of neuromuscular function. These combined effects ultimately lead to the inhibition of muscle atrophy and the restoration of nerve function. Consequently, the concept of the synergistic effect of inhibiting muscle atrophy and promoting nerve regeneration has the capacity to transform the traditional approach to PNI repair and find broad applications in PNI repair.